AU2002366951A1 - Novel nucleic acids and polypeptides - Google Patents

Novel nucleic acids and polypeptides

Info

Publication number
AU2002366951A1
AU2002366951A1 AU2002366951A AU2002366951A AU2002366951A1 AU 2002366951 A1 AU2002366951 A1 AU 2002366951A1 AU 2002366951 A AU2002366951 A AU 2002366951A AU 2002366951 A AU2002366951 A AU 2002366951A AU 2002366951 A1 AU2002366951 A1 AU 2002366951A1
Authority
AU
Australia
Prior art keywords
polypeptides
nucleic acids
novel nucleic
novel
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002366951A
Inventor
Vinod Asundi
Bryan J. Boyle
Rui-Hong Chen
Radoje T. Drmanac
Malabika Ghosh
Ryle W. Goodrich
Yunqing Ma
Feiyan Ren
Y. Tom Tang
Dunrui Wang
Jian-Rui Wang
Zhiwei Wang
Tom Wehrman
Gezhi Weng
Chongjun Xu
Aidong J. Xue
Jie Zhang
Qing A. Zhao
Ping Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Nuvelo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/128,558 external-priority patent/US20040219521A1/en
Application filed by Nuvelo Inc filed Critical Nuvelo Inc
Publication of AU2002366951A1 publication Critical patent/AU2002366951A1/en
Assigned to NUVELO, INC reassignment NUVELO, INC Request for Assignment Assignors: HYSEQ, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002366951A 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides Abandoned AU2002366951A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US33973901P 2001-12-10 2001-12-10
US60/339,739 2001-12-10
US33945301P 2001-12-11 2001-12-11
US60/339,453 2001-12-11
US36538402P 2002-03-14 2002-03-14
US36509102P 2002-03-14 2002-03-14
US60/365,091 2002-03-14
US60/365,384 2002-03-14
US37238102P 2002-04-12 2002-04-12
US37261502P 2002-04-12 2002-04-12
US60/372,381 2002-04-12
US60/372,615 2002-04-12
US10/128,558 US20040219521A1 (en) 2000-01-21 2002-04-22 Novel nucleic acids and polypeptides
US10/128,558 2002-04-22
US37604502P 2002-04-24 2002-04-24
US60/376,045 2002-04-24
PCT/US2002/039555 WO2003054152A2 (en) 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides

Publications (1)

Publication Number Publication Date
AU2002366951A1 true AU2002366951A1 (en) 2003-07-09

Family

ID=27574889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002366951A Abandoned AU2002366951A1 (en) 2001-12-10 2002-12-10 Novel nucleic acids and polypeptides

Country Status (4)

Country Link
EP (1) EP1504099A4 (en)
AU (1) AU2002366951A1 (en)
CA (1) CA2469941A1 (en)
WO (1) WO2003054152A2 (en)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9315698U1 (en) * 1993-10-14 1993-12-23 Buechi Lab Tech Evaporator flask for a rotary evaporator
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
KR100576674B1 (en) 2001-06-20 2006-05-10 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US20030068691A1 (en) * 2001-07-16 2003-04-10 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
ATE553193T1 (en) * 2001-08-30 2012-04-15 Arca Biopharma Inc METHODS AND MATERIALS RELATED TO STEM CELL GROWTH FACTOR-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES
MXPA04003057A (en) * 2001-10-04 2005-06-20 Immunex Corp Ul16 binding protein 4.
US7202056B2 (en) 2002-03-28 2007-04-10 Bristol-Myers Squibb Company Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
WO2003091436A1 (en) * 2002-04-26 2003-11-06 Fujisawa Pharmaceutical Co., Ltd. Novel 35 kd protein
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2004005335A2 (en) * 2002-07-05 2004-01-15 Borean Pharma A/S Multimerised growth hormone fusion proteins
DE60335552D1 (en) 2002-09-11 2011-02-10 Genentech Inc NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
CN1703524B (en) 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 Genes and polypeptides relating to human pancreatic cancer
PL378582A1 (en) 2003-03-19 2006-05-02 Biogen Idec Ma Inc. Nogo receptor binding protein
AU2004276646B2 (en) 2003-09-29 2012-07-12 Chugai Seiyaku Kabushiki Kaisha Protein expressed in NK cell
EP1679372B1 (en) * 2003-10-30 2009-02-18 Kazusa DNA Research Institute Foundation Novel plexin polypeptide, dna encoding the same and use thereof
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
RU2343158C2 (en) * 2004-01-27 2009-01-10 Ньювело, Инк. Gastrointestinal proliferative factor and its applications
GB0403491D0 (en) * 2004-02-17 2004-03-24 Univ Cambridge Tech Polypeptides, methods and means
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7901881B2 (en) 2004-04-09 2011-03-08 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
AU2005258335B2 (en) 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
EP1771578A2 (en) * 2004-07-23 2007-04-11 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of slim3 for neurodegenerative diseases
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
MX2008000253A (en) 2005-07-08 2008-04-02 Biogen Idec Inc Sp35 antibodies and uses thereof.
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
GB0522113D0 (en) * 2005-10-28 2005-12-07 Ares Trading Sa vWFA-domain containing proteins
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
GB0615287D0 (en) * 2006-08-01 2006-09-06 Ares Trading Sa Integral membrane protein
CA2665223A1 (en) * 2006-10-02 2008-05-29 The Scripps Research Institute An enzyme regulating ether lipid signaling pathways
GB0620735D0 (en) * 2006-10-18 2006-11-29 Ares Trading Sa Proteins
ES2553169T5 (en) 2007-07-02 2023-11-30 Oncomed Pharm Inc Compositions and methods for the treatment and diagnosis of cancer
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
AU2008294074B2 (en) * 2007-08-30 2015-01-22 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
CA2697992C (en) * 2007-10-04 2017-08-22 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
EP2217697B1 (en) * 2007-11-08 2015-06-10 Biogen MA Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
KR101855381B1 (en) 2008-04-09 2018-05-09 제넨테크, 인크. Novel compositions and methods for the treatment of immune related diseases
JP2011519959A (en) * 2008-05-13 2011-07-14 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ Methods for detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US8227417B2 (en) 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
EP3441458B9 (en) 2009-02-03 2023-08-23 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
KR101962476B1 (en) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 Immuno-conjugates and methods for producing them
WO2011004404A1 (en) * 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic variants for predicting risk of glaucoma
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
DK2528625T3 (en) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepines and their conjugates
CN114246952A (en) 2010-06-08 2022-03-29 基因泰克公司 Cysteine engineered antibodies and conjugates
CN105061534A (en) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 Substituted nucleotide analogs
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
EP3103810A3 (en) 2011-04-21 2017-03-08 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
RU2014101669A (en) 2011-07-15 2015-09-20 Онкомед Фармасьютикалс, Инк. AGENTS BINDING R-SPONDIN PROTEINS (RSPO), AND WAYS OF THEIR APPLICATION
CN103987407B (en) 2011-10-14 2016-08-24 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and conjugate thereof
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
CN104470541A (en) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 Lingo-2 antagonists for treatment of conditions involving motor neurons
NZ704269A (en) 2012-07-13 2016-05-27 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
JP6392763B2 (en) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ Pyrrolobenzodiazepine-antibody conjugate
MX364327B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-anti-cd22 antibody conjugates.
RS57694B1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
HUE039329T2 (en) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
ES2658888T5 (en) 2012-12-21 2021-10-19 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3021869B1 (en) 2013-07-16 2020-07-15 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
EA201690195A1 (en) 2013-08-12 2016-05-31 Дженентек, Инк. ANTIBODY CONJUGATE CONNECTIONS ON THE BASIS OF DIMER 1- (HLORMETHYL) -2,3-DIGYDRO-1H-BENZO [E] INDOL AND METHODS OF APPLICATION AND TREATMENT
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
PE20161394A1 (en) 2013-12-16 2017-01-06 Genentech Inc PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
JP6980384B2 (en) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and methods of use and treatment
MX371092B (en) 2013-12-16 2020-01-16 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112017003236A2 (en) 2014-09-12 2017-11-28 Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
CR20170099A (en) 2014-09-17 2017-07-19 Genentech Inc PIRROLOBENZODIAZEPINAS AND CONJUGADOS DE ANTIBERPOS-DISULFURO DE LAS SISAS
MX2017006770A (en) 2014-11-25 2018-02-09 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates.
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
JP2018504400A (en) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-1 antagonist and use for treatment of demyelinating disorders
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
AU2016325610B2 (en) 2015-09-25 2019-10-10 Genentech, Inc. Anti-TIGIT antibodies and methods of use
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
PT3544636T (en) 2017-02-08 2021-05-04 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20190141666A (en) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 Combination Therapy with Anti-AXL Antibody-Drug Conjugates
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (en) 2017-08-18 2022-04-21 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN112638944A (en) 2018-08-23 2021-04-09 西进公司 anti-TIGIT antibody
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (en) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity

Also Published As

Publication number Publication date
WO2003054152A3 (en) 2004-12-16
CA2469941A1 (en) 2003-07-03
EP1504099A4 (en) 2006-05-10
WO2003054152A2 (en) 2003-07-03
EP1504099A2 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
AU2002366951A1 (en) Novel nucleic acids and polypeptides
AU2002326877A1 (en) Novel nucleic acids and polypeptides
AU2002314709A1 (en) Novel nucleic acids and polypeptides
AU2001249251A1 (en) Novel nucleic acids and polypeptides
AU2001243142A1 (en) Novel nucleic acids and polypeptides
AU2001234944A1 (en) Novel nucleic acids and polypeptides
AU2001290548A1 (en) Novel nucleic acids and polypeptides
AU2001245280A1 (en) Novel nucleic acids and polypeptides
AU2001233041A1 (en) Novel nucleic acids and polypeptides
AU2001238347A1 (en) Novel nucleic acids and polypeptides
AU2001296235A1 (en) Novel nucleic acids and polypeptides
AU2002343417A1 (en) Novel nucleic acids and polypeptides
AU2001263006A1 (en) Novel nucleic acids and polypeptides
EP1381621A4 (en) Novel nucleic acids and polypeptides
AU2002368010A1 (en) Novel nucleic acids and secreted polypeptides
AU2001233017A1 (en) Novel nucleic acids and polypeptides
AU2002246502A1 (en) Nucleic acids and polypeptides
AU2001241511A1 (en) Novel nucleic acids and polypeptides
EP1368475A4 (en) Novel nucleic acids and polypeptides
AU2001292561A1 (en) Nucleic acids and polypeptides
AU2001250872A1 (en) Novel nucleic acids and polypeptides
WO2002016439A8 (en) Novel nucleic acids and polypeptides
AU2002367815A1 (en) Novel nucleic acids and secreted polypeptides
AU2002250419A1 (en) Novel nucleic acids and polypeptides
AU2001263005A1 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NUVELO, INC

Free format text: FORMER APPLICANT(S): HYSEQ, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application